NASDAQ:GHRS GH Research (GHRS) Stock Forecast, Price & News $11.98 +0.33 (+2.83%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$11.73▼$12.2450-Day Range$7.49▼$11.9852-Week Range$5.70▼$17.41Volume13,318 shsAverage Volume67,538 shsMarket Capitalization$605.23 millionP/E RatioN/ADividend YieldN/APrice Target$48.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media GH Research MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside302.8% Upside$48.25 Price TargetShort InterestBearish4.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.07) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector581st out of 983 stocksPharmaceutical Preparations Industry289th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.25, GH Research has a forecasted upside of 302.8% from its current price of $11.98.Amount of Analyst CoverageGH Research has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.96% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GHRS. Previous Next 3.8 News and Social Media Coverage News SentimentGH Research has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GH Research this week, compared to 1 article on an average week.Search Interest3 people have searched for GHRS on MarketBeat in the last 30 days. MarketBeat Follows5 people have added GH Research to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.55% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($1.07) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -22.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -22.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GH Research (NASDAQ:GHRS) StockGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Read More Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address GHRS Stock News HeadlinesJune 1, 2023 | americanbankingnews.comGH Research (NASDAQ:GHRS) Trading Down 5.8%May 17, 2023 | americanbankingnews.comGH Research PLC Expected to Post FY2027 Earnings of $0.00 Per Share (NASDAQ:GHRS)June 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 15, 2023 | americanbankingnews.comJMP Securities Raises GH Research (NASDAQ:GHRS) Price Target to $49.00May 14, 2023 | americanbankingnews.comGH Research (NASDAQ:GHRS) Shares Gap Up After Analyst UpgradeMay 12, 2023 | msn.comJMP Securities Maintains GH Research (GHRS) Outperform RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates GH Research (GHRS) Buy RecommendationMay 11, 2023 | msn.comGH Research: Q1 Earnings InsightsJune 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 11, 2023 | markets.businessinsider.comGH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment DeveloperMay 11, 2023 | finanznachrichten.deGH Research PLC: GH Research Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 11, 2023 | finance.yahoo.comGH Research Reports First Quarter 2023 Financial Results and Provides Business HighlightsApril 26, 2023 | americanbankingnews.comBELLUS Health (NASDAQ:BLU) versus GH Research (NASDAQ:GHRS) Financial ComparisonApril 5, 2023 | msn.comCompass Pathways, GH Research Among Top Psychedelic Movers Of TodayApril 5, 2023 | reuters.comUnilever Ghana LtdMarch 16, 2023 | seekingalpha.comGH Research (GHRS) Investor Presentation - SlideshowMarch 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Janux Therapeutics Inc (JANX), GH Research (GHRS)January 11, 2023 | markets.businessinsider.com2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key ProductsNovember 27, 2022 | news.yahoo.comA new General Hospital: Turning an iconic L.A. landmark into homeless housingNovember 10, 2022 | finanznachrichten.deGH Research PLC: GH Research Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 10, 2022 | finance.yahoo.comGH Research Reports Third Quarter 2022 Financial Results and Provides Business UpdatesOctober 8, 2022 | health.usnews.comMassachusetts General HospitalSeptember 28, 2022 | reuters.comGHRS.OQ - | Stock Price & Latest News | ReutersAugust 23, 2022 | finance.yahoo.comGH Research Reports Second Quarter 2022 Financial Results and Provides Business UpdatesMay 18, 2022 | finance.yahoo.comGH Research Reports First Quarter 2022 Financial Results and Provides Business UpdatesMarch 28, 2022 | finance.yahoo.comGH Research Reports Full Year 2021 Financial Results and Provides Business UpdatesMarch 18, 2022 | msn.comField Trip Health, Allied Among Top Psychedelic Movers Of TodaySee More Headlines GHRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GHRS Company Calendar Last Earnings5/11/2023Today6/02/2023Next Earnings (Estimated)8/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.25 High Stock Price Forecast$66.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+302.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.73% Return on Assets-13.48% Debt Debt-to-Equity RatioN/A Current Ratio24.81 Quick Ratio24.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.79 per share Price / Book2.50Miscellaneous Outstanding Shares50,520,000Free Float29,504,000Market Cap$605.23 million OptionableNot Optionable Beta0.73 Key ExecutivesMr. Florian Schonharting M.Sc. (Econ) (Age 53)Co-Founder & Non-Exec. Chairman Mr. Theis Terwey M.D. (Age 45)Co-Founder & CEO Mr. Magnus Halle (Age 24)Co-Founder & MD of Ireland Ms. Julie Ryan A.C.A. (Age 36)VP of Fin. Key CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXBioXcel TherapeuticsNASDAQ:BTAIAldeyra TherapeuticsNASDAQ:ALDXPhibro Animal HealthNASDAQ:PAHCZymeworksNYSE:ZYMEView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 1,740 shares on 5/16/2023Ownership: 0.099%PEAK6 Investments LLCBought 4,272 shares on 5/12/2023Ownership: 0.041%Renaissance Technologies LLCBought 10,800 shares on 5/12/2023Ownership: 0.021%FMR LLCSold 180,460 shares on 5/11/2023Ownership: 8.463%Tower Research Capital LLC TRC Bought 2,898 shares on 5/9/2023Ownership: 0.008%View All Institutional Transactions GHRS Stock - Frequently Asked Questions Should I buy or sell GH Research stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHRS shares. View GHRS analyst ratings or view top-rated stocks. What is GH Research's stock price forecast for 2023? 4 equities research analysts have issued 12-month price targets for GH Research's shares. Their GHRS share price forecasts range from $33.00 to $66.00. On average, they anticipate the company's stock price to reach $48.25 in the next year. This suggests a possible upside of 302.8% from the stock's current price. View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts. How have GHRS shares performed in 2023? GH Research's stock was trading at $9.72 at the beginning of the year. Since then, GHRS shares have increased by 23.3% and is now trading at $11.98. View the best growth stocks for 2023 here. Are investors shorting GH Research? GH Research saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,280,000 shares, an increase of 5.8% from the April 30th total of 1,210,000 shares. Based on an average trading volume of 68,900 shares, the short-interest ratio is currently 18.6 days. Approximately 5.0% of the company's shares are short sold. View GH Research's Short Interest. When is GH Research's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 22nd 2023. View our GHRS earnings forecast. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) announced its earnings results on Thursday, May, 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. What ETFs hold GH Research's stock? ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL). When did GH Research IPO? (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. What is GH Research's stock symbol? GH Research trades on the NASDAQ under the ticker symbol "GHRS." Who are GH Research's major shareholders? GH Research's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (8.46%), Mirae Asset Global Investments Co. Ltd. (0.19%), Geode Capital Management LLC (0.10%), AdvisorShares Investments LLC (0.09%), PEAK6 Investments LLC (0.04%) and Renaissance Technologies LLC (0.02%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GH Research's stock price today? One share of GHRS stock can currently be purchased for approximately $11.98. How much money does GH Research make? GH Research (NASDAQ:GHRS) has a market capitalization of $605.23 million. The company earns $-22,460,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. How can I contact GH Research? The official website for the company is www.ghres.com. The company can be reached via phone at 212-450-4000 or via email at investors@ghres.com. This page (NASDAQ:GHRS) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.